Top

Annals of Surgical Oncology

Published in:

01-10-2013 | Breast Oncology

Imaging Response and Residual Metastatic Axillary Lymph Node Disease after Neoadjuvant Chemotherapy for Primary Breast Cancer

Authors: Tina J. Hieken, MD, Judy C. Boughey, MD, Katie N. Jones, MD, Sejal S. Shah, MD, Katrina N. Glazebrook, MD

Published in: Annals of Surgical Oncology | Issue 10/2013

Abstract

Background

Although surgical management of the breast after neoadjuvant chemotherapy (NAC) may be governed by treatment response, axillary management continues to be determined by stage at presentation. Axillary ultrasound (AUS) with fine-needle aspiration (FNA) is used to detect lymph node (LN) metastases for pre-NAC staging, but imaging assessment of treatment response in the axilla remains undefined. We evaluated post-NAC axillary imaging and surgical pathology to understand how imaging might direct axillary surgery.

Methods

We evaluated pre- and post-NAC axillary imaging and clinicopathologic data in 272 patients who received NAC for primary breast cancer and underwent operation at our institution from 2010 to 2012. Treatment response on imaging was categorized as complete (CR), partial (PR), and none/progression (NR).

Results

Pre-NAC axillary staging classified patients as AUS negative/no FNA (n = 61), FNA/LN negative (n = 42), and FNA/LN positive (n = 169). Post-NAC axillary imaging included AUS (n = 146), MRI (n = 139), and PET-CT (n = 38). At operation, 128 of 272 patients (47 %) were LN positive: 23.3 % (24 of 103) of cN0 and 61.5 % (104 of 169) of cN1-AUS/FNA-positive patients at presentation. Of the 65 cN1-ypN0 patients, 58.1 % (25 of 43) had an imaging CR by US, 58.6 % (17 of 29) by MRI, and 84.6 % (11 of 13) by PET-CT. The sensitivity of post-NAC axillary imaging in detecting persistent LN metastases for cN1-AUS/FNA-positive patients was 69.8 % for US, 61.0 % for MRI, and 63.2 % for PET-CT.

Conclusions

Performance characteristics of AUS, MRI, and PET-CT, while informative, were inadequate to preclude surgical axillary staging of in breast cancer patients after NAC. Whether this information might be used to tailor surgical and postsurgical treatment requires further investigation.

Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer, 2009. Ann Oncol. 2009;20:1319–29.PubMedCrossRef

Kaufmann M, von Minckwitz G, Mamounas EP, et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol. 2012;19:1508–16.PubMedCrossRef

Boughey JC, Moriarty JP, Degnim AC, Gregg MS, Egginton JS, Long KH. Cost modeling of preoperative axillary ultrasound and fine-needle aspiration to guide surgery for invasive breast cancer. Ann Surg Oncol. 2010;17:953–8.PubMedCrossRef

Kuerer HM, Sahin AA, Hunt KK, et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg. 1999;230:72–8.PubMedCrossRef

Klauber-Demore N, Kuzmiak C, Rager EL, et al. High-resolution axillary ultrasound is a poor prognostic test for determining pathologic lymph node status in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer. Am J Surg. 2004;188:386–9.PubMedCrossRef

Alvarado R, Yi M, Le-Petross H, et al. The role for sentinel lymph node dissection after neoadjuvant chemotherapy in patients who present with node-positive breast cancer. Ann Surg Oncol. 2012;19:3177–84.PubMedCrossRef

Shigekawa T, Sugitani I, Takeuchi H, et al. Axillary ultrasound examination is useful for selecting patients optimally suited for sentinel lymph node biopsy after primary systemic chemotherapy. Am J Surg. 2012;204:487–93.PubMedCrossRef

Le-Petross H, McCall LM, Hunt K, et al. Role of axillary ultrasound after neoadjuvant chemotherapy in women with node-positive breast cancer (T1–4, N1–2, M0) at initial diagnosis (ACOSOG Z1071) (abstract). J Clin Oncol. 2012;30:1107.CrossRef

Cools-Lartigue J, Meterissian S. Accuracy of axillary ultrasound in the diagnosis of nodal metastasis in invasive breast cancer: a review. World J Surg. 2012;36:46–54.PubMedCrossRef

10.

Choi JJ, Kang BJ, Kim SH, et al. Role of sonographic elastography in the differential diagnosis of axillary lymph nodes in breast cancer. J Ultrasound Med. 2011;30:429–36.PubMed

11.

Li L, Mori S, Kodama M, Sakamoto M, Takahashi S, Kodama T. Enhanced sonographic imaging to diagnose lymph node metastasis: importance of blood vessel volume and density. Cancer Res. 2013;73:2082–92.PubMedCrossRef

12.

Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, et al. The role of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0–T4, N1–2) who receive neoadjuvant chemotherapy—results from the ACOSOG Z1071 trial (abstract). Cancer Res. 2012;72:S2–1.

13.

Ramirez SI, Scholle M, Buckmaster J, Kowdley GC. Assessment of the accuracy of ultrasound compared to magnetic resonance imaging in the ability to detect metastatic breast cancer to the axilla (abstract). Surg Tech Dev. 2012;2. doi:10.4081/std.2012.e4.

14.

Javid S, Segara D, Lotfi P, Raza S, Golshan M. Can breast MRI predict axillary lymph node metastasis in women undergoing neoadjuvant chemotherapy? Ann Surg Oncol. 2010;17:1841–6.PubMedCrossRef

15.

Williams A, Litton KJ, Borley A, Young P. Imaging the breast following neoadjuvant chemotherapy: does improvement of imaging findings in the axilla predict pathological response in the breast? Breast Cancer Res. 2012;14(Suppl 1):P30.CrossRef

16.

Luciani A, Dao TH, Lapeyre M, et al. Simultaneous bilateral breast and high-resolution axillary MRI of patients with breast cancer: preliminary results. AJR Am J Roentgenol. 2004;182:1059–67.PubMedCrossRef

17.

Koolen BB, Valdes Olmos RA, Wesseling J, et al. Early assessment of axillary response with F-FDG PET/CT during neoadjuvant chemotherapy in stage II–III breast cancer: implications for surgical management of the axilla. Ann Surg Oncol. 2013;20(7):2227–35. doi:10.1245/s10434-013-2902-0.PubMedCrossRef

18.

Mamounas EP, Anderson SJ, Dignam JJ, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol. 2012;30:3960–6.PubMedCrossRef

Title: Imaging Response and Residual Metastatic Axillary Lymph Node Disease after Neoadjuvant Chemotherapy for Primary Breast Cancer
Authors: Tina J. Hieken, MD
Judy C. Boughey, MD
Katie N. Jones, MD
Sejal S. Shah, MD
Katrina N. Glazebrook, MD
Publication date: 01-10-2013
Publisher: Springer US
Published in: Annals of Surgical Oncology / Issue 10/2013
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-013-3118-z

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Imaging Response and Residual Metastatic Axillary Lymph Node Disease after Neoadjuvant Chemotherapy for Primary Breast Cancer

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2013

Novel Factors to Improve Prediction of Nodal Positivity in Patients with Clinical T1/T2 Breast Cancers

Trends in Incidence and Management of Lobular Carcinoma In Situ: A Population-Based Analysis

Axillary Reverse Mapping: A Prospective Study in Women with Clinically Node Negative and Node Positive Breast Cancer

Is Postexcision, Preradiation Mammogram Necessary in Patients After Breast-Conserving Surgery with Negative Margins

Improving Breast Diagnostic Services with a Rapid Access Diagnostic and Support (RADS) Program

Prevalence of BRCA Mutations Among Women with Triple-Negative Breast Cancer (TNBC) in a Genetic Counseling Cohort